The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Abstract
The role of genetic and epigenetic factors in tumor initiation and progression is well documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA methyl transferases. (DNMTs) are the main proteins that are involved in regulating the chromatin conformation. Among these, histone deacetylases (HDAC) deacetylate the histone and induce gene repression thereby leading to cancer. In contrast, histone acetyl transferases (HATs) that include GCN5, p300/CBP, PCAF, Tip 60 acetylate the histones. HDAC inhibitors are potent drug molecules that can induce acetylation of histones at lysine residues and induce open chromatin conformation at tumor suppressor gene loci and thus resulting in tumor suppression. The key processes regulated by HDAC inhibitors include cell-cycle arrest, chemo-sensitization, apoptosis induction, upregulation of tumor suppressors. Even though FDA approved drugs are confined mainly to haematological malignancies, the research on HDAC inhibitors in glioblastoma multiforme and triple negative breast cancer (TNBC) are providing positive results. Thus, several combinations of HDAC inhibitors along with DNA methyl transferase inhibitors and histone methyl transferase inhibitors are in clinical trials. This review focuses on how HDAC inhibitors regulate the expression of coding and non-coding genes with specific emphasis on their anti-cancer potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
Liang, Y., Song, X., Li, Y., Chen, B., Zhao, W., Wang, L., Zhang, H., Liu, Y., Han, D., Zhang, N., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01206-5 · Cited by 373
RetractedWu, D., Zheng, Z., Zhang, Y., Fan, S., Zhang, Z.-F., Wang, Y., Zheng, Y., & Lu, J. L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1239-3 · Cited by 94
RetractedThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., et al. (2009) · Nature · doi:10.1038/nature07672 · Cited by 4,098
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
Functional Classification and Experimental Dissection of Long Noncoding RNAs
Kopp, F., & Mendell, J. T. (2018) · Cell · doi:10.1016/j.cell.2018.01.011 · Cited by 3,529
The Transcriptional Landscape of the Mammalian Genome
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005) · Science · doi:10.1126/science.1112014 · Cited by 3,499
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
The landscape of long noncoding RNAs in the human transcriptome
Iyer, M. K., Niknafs, Y. S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T. R., Prensner, J. R., Evans, J. R., Zhao, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3192 · Cited by 2,738
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Chang, P. V., Hao, L., Offermanns, S., & Medzhitov, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322269111 · Cited by 2,175
Torre, L. A., Siegel, R. L., & Jemal, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-24223-1_1 · Cited by 1,903
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
The Emergence of lncRNAs in Cancer Biology
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0209 · Cited by 1,770
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0033 · Cited by 1,364
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Histone acetylation and an epigenetic code
Turner, B. M. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<836::aid-bies9>3.0.co;2-x · Cited by 1,182
Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans
Adelman, K., & Lis, J. T. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3293 · Cited by 1,181
Calnan, D. R., & Brunet, A. (2008) · Oncogene · doi:10.1038/onc.2008.21 · Cited by 1,170
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Unravelling the Role of O-glycans in Influenza A Virus Infection
Mayr, J., Lau, K., Lai, J. C. C., Gagarinov, I. A., Shi, Y., McAtamney, S., Chan, R. W. Y., Nicholls, J., von Itzstein, M., & Haselhorst, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-34175-3 · Cited by 1,069
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Histones: annotating chromatin
Campos, E. I., & Reinberg, D. (2009) · Annual Review of Genetics · doi:10.1146/annurev.genet.032608.103928 · Cited by 852
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818
p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage
Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., & Berger, S. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1202 · Cited by 776
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Binding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678
Aurora-kinase inhibitors as anticancer agents
Keen, N., & Taylor, S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1502 · Cited by 675
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
DNA methylation and histone modifications: teaming up to silence genes
Fuks, F. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.08.002 · Cited by 644
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Roles of Aurora Kinases in Mitosis and Tumorigenesis
Fu, J., Bian, M., Jiang, Q., & Zhang, C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0208 · Cited by 614
Schwer, B., North, B. J., Frye, R. A., Ott, M., & Verdin, E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200205057 · Cited by 598
SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions
Vandewalle, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki965 · Cited by 542
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 510
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Weichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Childhood cerebellar tumours mirror conserved fetal transcriptional programs
Vladoiu, M. C., El-Hamamy, I., Donovan, L. K., Farooq, H., Holgado, B. L., Sundaravadanam, Y., Ramaswamy, V., Hendrikse, L. D., Kumar, S., Mack, S. C., et al. (2019) · Nature · doi:10.1038/s41586-019-1158-7 · Cited by 426
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Control of Transcriptional Elongation
Kwak, H., & Lis, J. T. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155440 · Cited by 409
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1
Doetzlhofer, A., Rotheneder, H., Lagger, G., Koranda, M., Kurtev, V., Brosch, G., Wintersberger, E., & Seiser, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5504 · Cited by 398
Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 394
Hurteau, G. J., Carlson, J. A., Spivack, S. D., & Brock, G. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1058 · Cited by 390
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.006 · Cited by 352
The histone variant H2A.Z in gene regulation
Giaimo, B. D., Ferrante, F., Herchenröther, A., Hake, S. B., & Borggrefe, T. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0274-9 · Cited by 349
Real-world evidence in the treatment of ovarian cancer
Eisenhauer, E. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx443 · Cited by 344
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Causes and Consequences of MicroRNA Dysregulation
Iorio, M. V., & Croce, C. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318250c001 · Cited by 333
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Vidal, M., & Gaber, R. F. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.12.6317 · Cited by 321
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Stern-Ginossar, N., Gur, C., Biton, M., Horwitz, E., Elboim, M., Stanietsky, N., Mandelboim, M., & Mandelboim, O. (2008) · Nature Immunology · doi:10.1038/ni.1642 · Cited by 315
Histone H2A variants in nucleosomes and chromatin: more or less stable?
Bonisch, C., & Hake, S. B. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks865 · Cited by 305
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Suraweera, A., Münch, C., Hanssum, A., & Bertolotti, A. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.003 · Cited by 302
Fabbri, M., Bottoni, A., Shimizu, M., Spizzo, R., Nicoloso, M. S., Rossi, S., Barbarotto, E., Cimmino, A., Adair, B., Wojcik, S. E., et al. (2011) · JAMA · doi:10.1001/jama.2010.1919 · Cited by 293
Carbonic anhydrase IX in oligodendroglial brain tumors
Järvelä, S., Parkkila, S., Bragge, H., Kähkönen, M., Parkkila, A.-K., Soini, Y., Pastorekova, S., Pastorek, J., & Haapasalo, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-1 · Cited by 291
Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing
Yeom, K.-H., Lee, Y., Han, J., Suh, M. R., & Kim, V. N. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl458 · Cited by 290
Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., & Sakai, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7786 · Cited by 288
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284
Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.011 · Cited by 276
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
Identification of Human Pancreatic Cancer Stem Cells
Li, C., Lee, C. J., & Simeone, D. M. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-59745-280-9_10 · Cited by 227
miRNA biogenesis: Biological impact in the development of cancer
Romero-Cordoba, S. L., Salido-Guadarrama, I., Rodriguez-Dorantes, M., & Hidalgo-Miranda, A. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955442 · Cited by 226
Histone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
Pastori, C., Kapranov, P., Penas, C., Peschansky, V., Volmar, C.-H., Sarkaria, J. N., Bregy, A., Komotar, R., St. Laurent, G., Ayad, N. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424220112 · Cited by 213
Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Morschhauser, F., Wilhelm, M., Pinter-Brown, L., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-11 · Cited by 212
Liang, Y., Han, H., Liu, L., Duan, Y., Yang, X., Ma, C., Zhu, Y., Han, J., Li, X., & Chen, Y. (2018) · Oncogenesis · doi:10.1038/s41389-018-0107-x · Cited by 205
HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
Nguyen, T. T. T., Zhang, Y., Shang, E., Shu, C., Torrini, C., Zhao, J., Bianchetti, E., Mela, A., Humala, N., Mahajan, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129049 · Cited by 201
Cloning and characterization of a novel human histone deacetylase, HDAC8
BUGGY, J. J., SIDERIS, M. L., MAK, P., LORIMER, D. D., MCINTOSH, B., & CLARK, J. M. (2000) · Biochemical Journal · doi:10.1042/bj3500199 · Cited by 197
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Sampath, D., Liu, C., Vasan, K., Sulda, M., Puduvalli, V. K., Wierda, W. G., & Keating, M. J. (2012) · Blood · doi:10.1182/blood-2011-05-351510 · Cited by 197
Zhang, X. D., Gillespie, S. K., Borrow, J. M., & Hersey, P. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.425.3.4 · Cited by 190
Ofir, M., Hacohen, D., & Ginsberg, D. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0344 · Cited by 183
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.24 · Cited by 180
Lucio-Eterovic, A. K., Cortez, M. A. A., Valera, E. T., Motta, F., Queiróz, R. G. D. P., Machado, H. R., Carlotti, C. G., Neder, L., Scrideli, C. A., & Tone, L. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-243 · Cited by 177
Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 177
miR-200b mediates post-transcriptional repression of ZFHX1B
Christoffersen, N. R., Silahtaroglu, A., Ørom, U. A., Kauppinen, S., & Lund, A. H. (2007) · RNA · doi:10.1261/rna.586807 · Cited by 175
Sankar, S., Theisen, E. R., Bearss, J., Mulvihill, T., Hoffman, L. M., Sorna, V., Beckerle, M. C., Sharma, S., & Lessnick, S. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0072 · Cited by 173
Progress in the chemotherapeutic treatment of osteosarcoma (Review)
Zhang, Y., Yang, J., Zhao, N., Wang, C., Kamar, S., Zhou, Y., He, Z., Yang, J., Sun, B., Shi, X., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9434 · Cited by 172
Zhang, Y., Gan, B., Liu, D., & Paik, J.-H. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.15954 · Cited by 167
Zhou, Q., Agoston, A. T., Atadja, P., Nelson, W. G., & Davidson, N. E. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0330 · Cited by 167
Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
Lee, S. J., Krauthauser, C., Maduskuie, V., Fawcett, P. T., Olson, J. M., & Rajasekaran, S. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-144 · Cited by 166
Marshall, G. M., Liu, P. Y., Gherardi, S., Scarlett, C. J., Bedalov, A., Xu, N., Iraci, N., Valli, E., Ling, D., Thomas, W. D., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002135 · Cited by 164
Zhang, Q., Zhang, Y., Wang, S. Z., Wang, N., Jiang, W. G., Ji, Y. H., & Zhang, S. L. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-1 · Cited by 164
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 160
Garding, A., Bhattacharya, N., Claus, R., Ruppel, M., Tschuch, C., Filarsky, K., Idler, I., Zucknick, M., Caudron-Herger, M., Oakes, C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003373 · Cited by 159
Hu, X., Xing, W., Zhao, R.-S., Tan, Y. H., Wu, X., Ao, L., Zhan, L., Yao, M., Yuan, M., Guo, W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01783-9 · Cited by 155
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 154
Woan, K. V., Lienlaf, M., Perez-Villarroel, P., Lee, C., Cheng, F., Knox, T. J., Woods, D. M., Barrios, K., Powers, J. J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 149
Sowa, Y., Orita, T., Minamikawa, S., Mizuno, T., Nomura, H., & Sakai, T. (1999) · PubMed · Cited by 146
Galanis, E., Anderson, S. K., Miller, C. R., Sarkaria, J. N., Jaeckle, K. A., Buckner, J. C., Ligon, K. L., Ballman, K. V., Moore, D. F., Nebozhyn, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox161 · Cited by 145
Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L. M., Antunes, A. S. L. M., Oehme, I., Pekrun, A., Pfister, S. M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0978-1 · Cited by 144
Acetylated histone H4 is preferentially associated with template-active chromatin.
Davie, J., & Candido, E. P. M. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.3574 · Cited by 144
P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer
Yao, D., Li, C., Rajoka, M. S. R., He, Z., Huang, J., Wang, J., & Zhang, J. C. (2020) · Theranostics · doi:10.7150/thno.46913 · Cited by 144
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Epigenetics of cancer stem cells: Pathways and therapeutics
Shukla, S., & Meeran, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.09.017 · Cited by 135
The application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 133
Bae, J. E., Hideshima, T., Tai, Y., Song, Y. Y., Richardson, P. G. G., Raje, N. S., Munshi, N. C., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/s41375-018-0062-8 · Cited by 131
Cao, X. X., Mohuiddin, I., Ece, F., McConkey, D. J., & Smythe, W. R. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.25.5.4539 · Cited by 123
Caslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
How do tumor cells respond to HDAC inhibition?
Newbold, A., Falkenberg, K. J., Prince, H. M., & Johnstone, R. W. (2016) · FEBS Journal · doi:10.1111/febs.13746 · Cited by 121
High-resolution human core-promoter prediction with CoreBoost_HM
Wang, X., Xuan, Z., Zhao, X., Li, Y., & Zhang, M. Q. (2008) · Genome Research · doi:10.1101/gr.081638.108 · Cited by 120
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Frumm, S. M., Fan, Z. P., Ross, K. N., Duvall, J. R., Gupta, S., VerPlank, L., Suh, B., Holson, E. B., Wagner, F. F., Smith, W. B., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.020 · Cited by 118
Hsieh, T.-H., Hsu, C., Tsai, C.-F., Long, C., Wu, C., Wu, D., Lee, J.-N., Chang, W.-C., & Tsai, E. (2014) · Molecular Therapy · doi:10.1038/mt.2014.247 · Cited by 110
Hrzenjak, A., Kremser, M., Strohmeier, B., Moinfar, F., Zatloukal, K., & Denk, H. (2008) · The Journal of Pathology · doi:10.1002/path.2434 · Cited by 108
Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S., Varma, A. K., Vandergrift, W. A., Patel, S. J., et al. (2015) · PubMed · Cited by 106
Aggarwal, R. R., Thomas, S., Pawłowska, N., Bartelink, I. H., Grabowsky, J. A., Jahan, T. M., Cripps, A., Harb, A., Leng, J. X., Reinert, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5350 · Cited by 102
Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Macdonald, K., Gulyas, S., Clark, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl081 · Cited by 101
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 100
Lung cancer: potential targets for immunotherapy
Tartour, É., & Zitvogel, L. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70159-0 · Cited by 99
Bora-Singhal, N., Mohankumar, D., Saha, B., Colin, C., Lee, J. Y., Martin, M. W., Zheng, X., Coppola, D., & Chellappan, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-61295-6 · Cited by 99
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression
Fiziev, P. P., Akdemir, K. C., Miller, J. P., Keung, E. Z.-Y., Samant, N. S., Sharma, S., Natale, C. A., Terranova, C. J., Maitituoheti, M., Amin, S. B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.078 · Cited by 97
Ma, H., Chang, H., Yang, W., Lu, Y., Hu, J., & Jin, S. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1123-y · Cited by 97
Bao, L., Diao, H., Dong, N., Su, X., Wang, B., Mo, Q., Yu, H., Wang, X., & Chen, C. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9347-8 · Cited by 96
Vandermeers, F., Hubert, P., Delvenne, P., Mascaux, C., Grigoriu, B. D., Burny, A., Scherpereel, A., & Willems, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1579 · Cited by 94
Halsall, J. A., & Turner, B. M. (2016) · BioEssays · doi:10.1002/bies.201600070 · Cited by 94
Brown, J. R., Hanna, M., Tesar, B. M., Werner, L. L., Pochet, N. L. M. M., Asara, J. M., Wang, Y. E., Cin, P. D., Fernandes, S. M., Thompson, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2342 · Cited by 93
Lung Cancer and Personalized Medicine
Ahmad, A., & Gadgeel, S. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1 · Cited by 91
Histone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors
Blagosklonny, M. V., Trostel, S. Y., Kayastha, G., Demidenko, Z. N., Vassilev, L. T., Romanova, L. Y., Bates, S. E., & Fojo, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3433 · Cited by 89
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 89
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Mamdani, H. M., & Jalal, S. I. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.582370 · Cited by 88
Neužil, J., Swettenham, E., & Gellert, N. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.074 · Cited by 87
Retinoids induce stem cell differentiation via epigenetic changes
Gudas, L. J. (2013) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.08.002 · Cited by 85
Epping, M. T., Wang, L., Plumb, J. A., Lieb, M., Gronemeyer, H., Brown, R. E., & Bernards, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702518104 · Cited by 85
Xiao, Y., Lin, F., & Lin, W.-C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015808118 · Cited by 85
Niegisch, G., Knievel, J., Koch, A., Hader, C., Fischer, U., Albers, P., & Schulz, W. A. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.06.015 · Cited by 82
Sonnemann, J., Dreyer, L., Hartwig, M., Palani, C. D., Hong, L. T. T., Klier, U., Bröker, B. M., Völker, U., & Beck, J. F. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0227-8 · Cited by 81
Long non-coding RNAs in cancer invasion and metastasis
Shen, X.-H., Qi, P., & Du, X. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.75 · Cited by 80
Maiti, A., Qi, Q., Peng, X., Yan, L., Takabe, K., & Hait, N. C. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4796 · Cited by 80
Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy
Koukourakis, M. I., & Giatromanolaki, A. N. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1490041 · Cited by 79
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0598-5 · Cited by 78
Recent advances in class IIa histone deacetylases research
Asfaha, Y., Schrenk, C., Avelar, L. A. A., Hamacher, A., Pflieger, M., Kassack, M. U., & Kurz, T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115087 · Cited by 78
Noce, M. L., Paino, F., Mele, L. L., Papaccio, G., Regad, T., Lombardi, A., Papaccio, F., Desiderio, V., & Tirino, V. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0978-x · Cited by 77
Ban, J., Aryee, D. N. T., Fourtouna, A., van der Ent, W., Kauer, M., Niedan, S., Machado, I., Galindo, C. R., Tirado, Ò. M., Schwentner, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1736 · Cited by 75
DuBois, S. G., Groshen, S. G., Park, J. R., Haas-Kogan, D. A., Yang, X., Geier, E. G., Chen, E., Giacomini, K., Weiss, B., Cohn, S. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3240 · Cited by 75
Roh, M.-S., Kim, C. W., Park, B. S., Kim, G. C., Jeong, J. H., Kwon, H., Suh, D. J., Cho, K. H., Yee, S.-B., & Yoo, Y. H. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000038037.68908.6e · Cited by 72
Yang, T., Chen, W., Shi, P.-C., Liu, M.-R., Jiang, T., Hu, S., Wang, J., Fan, R., Pei, D., & Song, J. H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01633-8 · Cited by 72
Sacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3765 · Cited by 70
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
Paik, P. K., & Krug, L. M. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c5e366 · Cited by 64
Sborov, D. W., Canella, A., Hade, E. M., Mo, X. M., Khountham, S., Wang, J., Ni, W., Poi, M. J., Coss, C. C., Liu, Z., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1298751 · Cited by 63
Yang, Y., Balch, C., Kulp, S. K., Mand, M. R., Nephew, K. P., & Chen, C. (2009) · Neoplasia · doi:10.1593/neo.09204 · Cited by 60
Chen, D., Pan, B., Huang, J., Zhang, K., Cui, S.-Y., De, W., Wang, R., & Chen, L. (2014) · Oncotarget · doi:10.18632/oncotarget.1948 · Cited by 60
Hui, K. F., & Chiang, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28924 · Cited by 60
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer
Gray, J. E., Cubitt, C. L., Zhang, S., & Chiappori, A. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19848 · Cited by 58
Sharma, V., Koul, N., Joseph, C., Dixit, D., Ghosh, S., & Sen, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00844.x · Cited by 57
Bandolik, J. J., Hamacher, A., Schrenk, C., Weishaupt, R., & Kassack, M. U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123052 · Cited by 57
Kauh, J. S. W., Fan, S., Xia, M., Yue, P., Yang, L. P. H., Khuri, F. R., & Sun, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010376 · Cited by 56
Activation of p21 by HDAC Inhibitors Requires Acetylation of H2A.Z
Bellucci, L., Dalvai, M., Kocanova, S., Moutahir, F., & Bystricky, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054102 · Cited by 55
Valproic acid for the treatment of pediatric malignant glioma
Driever, P. H., Knüpfer, M. M., Cinatl, J. J., & Wolff, J. E. A. (1999) · Klinische Pädiatrie · doi:10.1055/s-2008-1043809 · Cited by 55
Park, J., Jong, H.-S., Kim, S. G., Jung, Y., Lee, K., Lee, J., Kim, D., Bang, Y., & Kim, T. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0260-8 · Cited by 55
SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms
Xu, C., Sang, B., Liu, G., Li, J., Zhang, X. D., Liu, L. X., Thorne, R. F., & Wu, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa063 · Cited by 55
LIF- and IL-6-Induced Acetylation of STAT3 at Lys-685 through PI3K/Akt Activation
Ohbayashi, N., Ikeda, O., Taira, N., Yamamoto, Y., Muromoto, R., Sekine, Y., Sugiyama, K., Honjoh, T., & Matsuda, T. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.1860 · Cited by 54
Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Motoyama, S., & Ogawa, J. (2010) · Tumor Biology · doi:10.1007/s13277-010-0066-0 · Cited by 53
Targeting histone deacetylases for the treatment of disease
Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00571.x · Cited by 53
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Adams, C. M., Hiebert, S. W., & Eischen, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1751 · Cited by 53
Association of histone deacetylase expression with histology and prognosis of ovarian cancer
Yano, M., Yasuda, M., Sakaki, M., Nagata, K., Fujino, T., Arai, E., Hasebe, T., Miyazawa, M., Miyazawa, M., Ogane, N., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7726 · Cited by 52
Negmeldin, A. T., Knoff, J. R., & Pflum, M. K. H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.076 · Cited by 51
Zhang, Y., Ishida, C. T., Ishida, W., Lo, S.-F. L., Zhao, J., Shu, C., Bianchetti, E., Kleiner, G., Sanchez‐Quintero, M. J., Quinzii, C. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0260 · Cited by 49
Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML
Yu, X., Li, H., Hu, P., Qing, Y., Wang, X., Zhu, M., Wang, H., Wang, Z., Xu, J., Guo, Q., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.154 · Cited by 48
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Murahari, S., Jalkanen, A., Kulp, S. K., Chen, C., Modiano, J. F., London, C. A., & Kisseberth, W. C. (2017) · BMC Cancer · doi:10.1186/s12885-017-3046-6 · Cited by 47
HDAC inhibitors tested in phase III trial
Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0224-2 · Cited by 47
Burke, B., Eden, C., Pérez, C., Belshoff, A. C., Hart, S., Plaza-Rojas, L., Reyes, M. D., Prajapati, K., Voelkel‐Johnson, C., Henry, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00699 · Cited by 47
Genome-wide characterization of lncRNAs in acute myeloid leukemia
Lei, L., Xia, S., Liu, D., Li, X., Feng, J. Q., Zhu, Y., Hu, J., Xia, L., Guo, L., Chen, F., et al. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx007 · Cited by 46
Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells
Pastorino, O., Gentile, M. T., Mancini, A., Gaudio, N. D., Costanzo, A. D., Bajetto, A., Franco, P., Altucci, L., Florio, T., Stoppelli, M. P., et al. (2019) · Cancers · doi:10.3390/cancers11060747 · Cited by 46
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
The Role of Short Chain Fatty Acids in Inflammation and Body Health
Du, Y., He, C., An, Y., Huang, Y., Zhang, H., Fu, W., Wang, M., Shan, Z., Xie, J., Yang, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137379 · Cited by 384
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Metadata
- Authors
- Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 277
- Pages
- 119504
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3152901913
- Cited by
- 345
- References
- 256
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.